Company Profile
Verastem, Inc. Stock Price, News & Catalysts
- Ticker:
- VSTM
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
6.86 USD (-0.44%)
Close
Last updated: August 24, 2026
335M USD
Market cap
Why the stock is moving
As of Aug 24, 2026, VSTM closed down 0.44% at $6.86. No new same-company headline was identified in the current news window.
Company overview
Business overview
Verastem is a biotechnology company focused on oncology and rare-disease pathways, including targeted cancer programs. Its story has centered on developing therapies for difficult-to-treat tumors.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Verastem sits in specialty oncology biotechnology.
Business Model Characteristics
The business depends on clinical validation, product development, and the ability to create a focused cancer franchise.
Position Within the Biotechnology Landscape
Verastem is a catalyst-driven oncology name whose stock reacts to development and strategic milestones.
Future catalysts
- Verastem’s catalysts are avutometinib / defactinib and the ovarian-cancer / RAF-pathway development path. Investors will watch whether the combination story can keep building a credible oncology franchise.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Verastem, Inc. (VSTM)?
Verastem, Inc. (VSTM) most recently closed at 6.86 USD, a -0.44% move versus the previous session.
What is the market cap of Verastem, Inc. (VSTM)?
Verastem, Inc. currently has a market capitalization of 335M USD on BioPharmSignal.
What does Verastem, Inc. do?
Verastem is a biotechnology company focused on oncology and rare-disease pathways, including targeted cancer programs. Its story has centered on developing therapies for difficult-to-treat tumors.
On which exchange is VSTM stock listed?
Verastem, Inc. (VSTM) is associated with NASDAQ, United States, Biopharma.
What is avutometinib?
Verastem’s catalysts are avutometinib / defactinib and the ovarian-cancer / RAF-pathway development path.
Which conditions is Verastem, Inc. targeting with avutometinib?
Verastem, Inc. is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Verastem, Inc. describe recent progress with avutometinib?
Verastem’s catalysts are avutometinib / defactinib and the ovarian-cancer / RAF-pathway development path.
What is defactinib?
Verastem’s catalysts are avutometinib / defactinib and the ovarian-cancer / RAF-pathway development path.